Monday, May 25, 2026
← Back to archivePolicy
Policy•Fierce Pharma•May 25, 2026
Europe's CHMP gives thumbs up to AZ's breast cancer drug after thumbs down from FDA adcomm
background ▾
- •EMA CHMP positive opinion for Etcamah contradicts recent FDA AdComm rejection recommendation, indicating significant transatlantic regulatory divergence on this breast cancer asset
- •AstraZeneca retains path to European market access and potential commercial viability even if FDA denies approval, though US market represents larger revenue opportunity
- •Timeline and grounds for EMA's expedited positive opinion versus FDA committee concerns remain unclear and warrant investigation into differing efficacy/safety interpretations
AstraZenecaNovo NordiskEtcamahWegovy
→ Read original articlePolicy•Fierce Pharma•May 25, 2026
Designing an agentic, future‑ready tech roadmap for emerging pharma
background ▾
- •Emerging pharma companies are under increasing pressure to integrate agentic AI into their technology infrastructure
SynOx TherapeuticsZS
→ Read original articlePolicy•Fierce Pharma•May 25, 2026
AbbVie plots 85 summer layoffs tied to Allergan unit in California
background ▾
- •85 jobs eliminated at AbbVie's Allergan Irvine site on July 20, 2024, per WARN notice
AbbVieAllergan
→ Read original articlePolicy•Fierce Pharma•May 25, 2026
AstraZeneca, Daiichi beat Gilead to first-line TNBC with FDA nod for Datroway
background ▾
- •Datroway is the first TROP2 ADC approved for first-line TNBC, providing AstraZeneca/Daiichi with a critical first-mover advantage in a high-value indication
- •The approval indicates an active three-way competition with Gilead and others developing TROP2 ADCs, suggesting the market may support multiple competitors
- •Datroway's pricing, formulary placement, and payer coverage will be critical determinants of commercial success; watch for rapid follow-on approvals from competitors and early real-world uptake data
AstraZenecaDaiichi SankyoGilead SciencesDatroway (datopotamab deruxtecan)
→ Read original articlePolicy•KFF•May 23, 2026
Is The U.S. Stepping Up In The Fight Against Ebola?
background ▾
- •The DRC Ebola outbreak is among the largest on record with 746 suspected cases and 176 deaths, declared a PHEIC with cross-border spread to Uganda, requiring sustained multinational response
- •U.S. response capacity is significantly altered due to policy changes affecting foreign assistance and global health infrastructure, creating operational uncertainties compared to prior outbreak responses
- •Monitor whether the U.S. maintains sustained funding and coordination with WHO and international partners, and whether the outbreak escalates further in DRC and surrounding regions
Market Access
Market Access•Fierce Pharma•May 25, 2026
AbbVie, GSK race up patient reputation leaderboard in the UK
background ▾
- •AbbVie and GSK have improved patient reputation rankings in the UK market
AbbVieGSK
→ Read original articleMarket Access•Fierce Pharma•May 25, 2026
Tyra creates awareness day with patient advocates to shine light on a rare cancer
background ▾
- •Tyra is executing disease awareness strategy ahead of potential product launch for upper tract urothelial cancer
Tyra Biosciences
→ Read original articleMarket Access•Endpoints News•May 23, 2026
Inside Makary’s ouster; Another win for Lilly’s triple-G; and more
background ▾
- •This is a newsletter teaser with insufficient detail to extract actionable intelligence for pharma professionals
Eli Lilly
→ Read original articleMarket Access•Endpoints News•May 22, 2026
Why one health AI unicorn is giving away its service for free
background ▾
- •Health AI companies are using free access as a competitive differentiation strategy in a saturated market
Market Access•Endpoints News•May 22, 2026
Novartis says Avidity's science could apply beyond muscular dystrophies
background ▾
- •Novartis is actively developing a pipeline expansion strategy for Avidity's technology platform to justify the substantial $12 billion acquisition investment
- •The science has potential applications across multiple indications beyond the original muscular dystrophy target, suggesting broader commercial potential
NovartisAvidity Biosciences
→ Read original articleClinical Trials
Clinical Trials•Fierce Pharma•May 25, 2026
Fierce Pharma Asia—Merck-Kelun ADC’s triple wins; Tools in China licensing deals; Takeda’s $885M antitrust loss
background ▾
- •Merck-Kelun's sac-TMT demonstrated positive Phase 3 results across three trials, advancing a multi-indication ADC pipeline asset with commercial potential in oncology
- •Takeda faced the first federal jury verdict holding a drugmaker liable in a pay-for-delay patent settlement, setting precedent for antitrust enforcement in pharma
- •Watch for regulatory filings and approval timelines for sac-TMT; monitor whether Takeda's verdict triggers similar litigation against other companies with pay-for-delay settlements
Merck & Co.Kelun-BiotechTakedasac-TMT
→ Read original articleClinical Trials•Fierce Biotech•May 22, 2026
Has Novartis’ T-Charge been overtaken by in vivo CAR-Ts? Execs argue there’s room for both
background ▾
- •Novartis has only one T-Charge CAR-T in clinical development (rap-cel) after discontinuing PHE885, while competitors are rapidly consolidating the in vivo CAR-T space through major acquisitions.
- •Rap-cel shows acceptable safety and competitive efficacy in lymphoma phase 2 trials, but durability data—a key differentiator Novartis claims for T-Charge—remain incomplete; the company targets 2028 submission for lupus nephritis but has not clearly articulated oncology development path.
- •Monitor rap-cel phase 2 data readouts, in vivo CAR-T clinical efficacy and durability claims, and Novartis' collaboration with Legend Biotech to incorporate T-Charge into DLL3-targeted CAR-Ts (LB2102).
NovartisEli LillyGilead Sciencesrapcabtagene autoleucelrap-celYTB323
→ Read original articleClinical Trials•Fierce Biotech•May 22, 2026
OSE turns up the heat on ovarian cancer with phase 2, Keytruda-supported win
background ▾
- •OSE2101-Keytruda combination achieved statistically significant PFS improvement (4.1 vs. 2.8 months) in platinum-sensitive recurrent ovarian cancer maintenance setting, with pronounced benefit in platinum-responsive patients
- •Design limitation: absence of Keytruda monotherapy control arm prevents definitive attribution of benefit to the vaccine component versus the checkpoint inhibitor alone
- •Watch for phase 3 readout timing in non-small cell lung cancer and additional investigator-sponsored trial data in ovarian, pancreatic, and lung cancers expected this year; commercial viability depends on clarifying OSE2101's independent value proposition in combination regimens
OSE ImmunotherapeuticsMerck & Co.OSE2101Keytrudapembrolizumab
→ Read original articleClinical Trials•Fierce Pharma•May 25, 2026
ASCO: Merck, Kelun's sac-TMT ADC combo beats Keytruda by 65% on progression in first-line lung cancer
background ▾
- •sac-TMT + Keytruda achieved a 65% reduction in progression-free survival or death risk versus Keytruda alone in first-line PD-L1-positive NSCLC, a clinically meaningful improvement in a crowded market segment
- •TROP2-directed ADCs are emerging as a successful platform; this combination approach could drive new label indications and commercial opportunity for both Merck and Kelun
- •Watch for full Phase 3 data publication, regulatory submissions (FDA/EMA), and head-to-head comparisons with competing ADC combinations (e.g., Lilly's datopotamab deruxtecan regimens)
MerckKelunsac-TMTKeytrudapembrolizumab
→ Read original articleClinical Trials•STAT News•May 22, 2026
A CDC page on mpox caught in political crosshairs
background ▾
- •Eli Lilly's obesity drug achieved weight loss comparable to bariatric surgery in late-stage trials, suggesting potential market leadership if approved.
- •Approximately 11% discontinuation rate due to adverse events and high overall side effect burden may limit commercial potential despite superior efficacy.
- •Watch for regulatory feedback on risk-benefit profile and label restrictions, and real-world adherence data post-approval.
Eli LillyEli Lilly next-generation obesity drug (unnamed)
→ Read original article